KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE...

Hematological Oncology 2017 / 06 Vol. 35

KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL LYMPHOMA RECEIVING HIGH-DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL

Ferrero, S., Rossi, D., Bruscaggin, A., Evangelista, A., Di Rocco, A., Spina, V., Stefoni, V., Ghione, P., Barbero, D., Monitillo, L., Gomes Da Silva, M., Santoro, A., Molinari, A., Ferreri, A., Picci
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
35
Language:
english
Journal:
Hematological Oncology
DOI:
10.1002/hon.2437_83
Date:
June, 2017
File:
PDF, 120 KB
english, 2017
Conversion to is in progress
Conversion to is failed